Ovoca Bio plc

ISE:OVXA Stock Report

Market Cap: €1.2m

Ovoca Bio Past Earnings Performance

Past criteria checks 0/6

Ovoca Bio's earnings have been declining at an average annual rate of -16.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.

Key information

-16.1%

Earnings growth rate

-15.6%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth raten/a
Return on equity-177.5%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Ovoca Bio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ISE:OVXA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-410
31 Mar 240-520
31 Dec 230-520
30 Jun 230-230
31 Mar 230-440
31 Dec 220-650
30 Sep 220-760
30 Jun 220-860
31 Mar 220-760
31 Dec 210-560
30 Jun 210-340
31 Mar 210-330
31 Dec 200-220
30 Jun 200-320
31 Mar 200-220
31 Dec 190-120
30 Jun 190-220
31 Mar 190-220
31 Dec 180-210
30 Jun 180-110
31 Mar 180-110
31 Dec 170010
30 Sep 170120
30 Jun 170220
31 Mar 170020
31 Dec 160-120
30 Sep 160-210
30 Jun 160-310
31 Mar 160-310
31 Dec 150-210
30 Sep 150-510
30 Jun 150-710
31 Mar 150-720
31 Dec 140-720
30 Sep 140-820
30 Jun 140-910

Quality Earnings: OVXA is currently unprofitable.

Growing Profit Margin: OVXA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: OVXA is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.

Accelerating Growth: Unable to compare OVXA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVXA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).

Return on Equity

High ROE: OVXA has a negative Return on Equity (-177.53%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:49
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ovoca Bio plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GreenGrowth Equities & Company Research